Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis

Monoclonal antibodies (mAbs) are increasingly used to treat rheumatoid arthritis (RA). At present, anti-tumor necrosis factor-α drugs (infliximab, adalimumab, certolizumab pegol, and golimumab), rituximab, and tocilizumab are approved for RA treatment. This review focuses on the pharmacokinetics and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacokinetics 2015-11, Vol.54 (11), p.1107-1123
Hauptverfasser:	Ternant, David, Bejan-Angoulvant, Theodora, Passot, Christophe, Mulleman, Denis, Paintaud, Gilles
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacokinetics Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Antirheumatic Agents - pharmacokinetics Drug Approval Half-Life Humans Internal Medicine Medicine Medicine & Public Health Pharmacology/Toxicology Pharmacotherapy Review Article Rheumatic Fever - drug therapy Rheumatic Fever - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!